Company Overview
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare; dental and vision insurance; and oncology plans. It also sells medicines. Auna S.A. was founded in 1989 and is based in Luxembourg, Luxembourg.
Why Investors Should Care
Revenue has grown at a 21.4% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.39B (-0.0% YoY); net profit $97.61M.
- Trailing 12 Months Year-on-year growth — revenue +13.2%, earnings -64.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.39% |
| 1 Year: | 13.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -64.00% |
Stock Price Performance
| 1 Year: | -16.83% |
| 6 Months: | +9.85% |
| 3 Months: | +15.93% |
| 1 Month: | -1.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.51 · Neutral
P/E of 87.33 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 21.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 87.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AUNA Auna SA PHARMA | 5.24 | 87.33 | $157.93M | 0.00% | 11.21% | 1.62% | 21.39% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.04B | 1.09B | 1.12B | 1.13B | 1.18B |
| Cost of Revenue | 660.25M | 659.54M | 698.00M | 703.59M | 746.52M |
| Gross Profit | 381.62M | 434.40M | 419.00M | 428.71M | 431.06M |
| Operating Expenses | 236.06M | 262.40M | 259.00M | 275.44M | 276.38M |
| Operating Income | 145.56M | 172.00M | 160.00M | 153.27M | 154.68M |
| EBITDA | 238.14M | 287.06M | 270.31M | 40.65M | 192.19M |
| Interest Expense | 123.23M | 99.47M | 116.00M | 75.97M | 118.23M |
| Pretax Income | 61.53M | 132.28M | 97.00M | -91.75M | 16.46M |
| Tax Provision | 23.56M | 48.26M | 44.00M | -27.65M | 6.97M |
| Net Income | 35.43M | 81.98M | 48.00M | -68.39M | 6.55M |
| Diluted EPS | 0.48 | 1.10 | 0.65 | -0.92 | 0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 2.45B | 3.88B | 4.39B | 4.39B |
| Cost of Revenue | - | 1.57B | 2.44B | 2.66B | 2.72B |
| Gross Profit | - | 879.70M | 1.44B | 1.73B | 1.66B |
| Operating Expenses | - | 636.56M | 889.62M | 979.11M | 1.03B |
| Operating Income | - | 243.14M | 545.73M | 746.18M | 631.27M |
| EBITDA | - | 299.14M | 647.30M | 887.03M | 856.65M |
| Interest Expense | - | 208.50M | 535.72M | 484.10M | 434.97M |
| Pretax Income | - | -47.45M | -124.17M | 183.78M | 199.25M |
| Tax Provision | - | 29.38M | 90.17M | 59.82M | 88.35M |
| Net Income | - | -85.61M | -253.92M | 110.27M | 97.61M |
| Diluted EPS | - | -1.16 | -3.44 | 1.63 | 1.32 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 6.59B | 7.69B | 7.08B | 7.30B |
| Current Assets | - | 1.20B | 1.55B | 1.70B | 1.84B |
| Cash & Equivalents | - | 208.69M | 241.13M | 235.75M | 335.44M |
| Inventory | - | 87.58M | 130.52M | 143.76M | 164.80M |
| Receivables | - | 574.17M | 860.92M | 961.89M | 1.04B |
| Total Liabilities | - | 5.04B | 5.91B | 5.46B | 5.53B |
| Current Liabilities | - | 2.85B | 1.69B | 1.95B | 1.67B |
| Long Term Debt | - | 1.31B | 3.38B | 2.97B | 3.22B |
| Total Debt | - | 3.51B | 3.92B | 3.77B | 3.66B |
| Total Equity | - | 1.06B | 1.47B | 1.48B | 1.60B |
| Shares Outstanding | - | 73.92M | 73.92M | 73.97M | 74.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 162.64M | 582.41M | 668.50M | 662.50M |
| Investing Cash Flow | - | -3.21B | -173.15M | -236.82M | -80.25M |
| Financing Cash Flow | - | 3.13B | -370.00M | -418.12M | -487.10M |
| Capital Expenditure | - | -151.97M | -165.16M | -141.85M | -144.68M |
| Free Cash Flow | - | 10.67M | 417.25M | 526.65M | 517.82M |
| Net Change in Cash | - | 83.85M | 39.26M | 13.56M | 95.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 35.9% | 37.0% | 39.3% | 37.9% |
| Operating Margin % | - | 9.9% | 14.1% | 17.0% | 14.4% |
| Net Margin % | - | -3.5% | -6.6% | 2.5% | 2.2% |
| ROE % | - | -8.0% | -17.3% | 7.5% | 6.1% |
| ROCE % | - | 6.5% | 9.1% | 14.5% | 11.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.71% | 1.12M | $5.69M |
| 2 | Morgan Stanley | 1.91% | 574.37K | $2.93M |
| 3 | Jane Street Group, LLC | 1.91% | 574.12K | $2.93M |
| 4 | Renaissance Technologies, LLC | 1.88% | 566.10K | $2.89M |
| 5 | Marshall Wace LLP | 1.61% | 484.57K | $2.47M |
| 6 | Two Sigma Investments, LP | 1.05% | 315.69K | $1.61M |
| 7 | Verde Servicos Internacionais S.a. | 1.02% | 308.21K | $1.57M |
| 8 | Pekin Hardy Strauss, Inc. | 0.98% | 294.23K | $1.50M |
| 9 | UBS Group AG | 0.67% | 200.79K | $1.02M |
| 10 | Mount Lucas Management LP | 0.58% | 175.00K | $892.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUNA
Auna S.A. (AUNA) Q2 Earnings Miss Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPanlZQnhranNTcENDU3c0Q0tyMnhaajNFblYySWdCMzRVNDk1TkR2Zk1pcGMzNklfZlRldG9HS19EWFd3b2pmZ1pqbHJpSFFVeVpKOGE5b3l6SmRiMlZQdkI2ZDdjd2dVRFlEYlU3WURzNnhnbnJnTThpQTVIUFZXR1U5SHZVSWNsZk5mWE…
Precision Trading with Auna Sa Class A (AUNA) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQb0NtNjlhSDJoNGlvRnU2b0pXNnYwa1poSC05LUg0N3MtV2IyWmVZdGE4S3E2aWFjYUZ1WkVDN0VoNVR0OFZKRFk4enJ6enZDaXQ1cDVQMkpYM1k3UFZxT2ZTckVLb2FmR3lVWlJNZzkzOHFwWVRRV2wtN2VyNTU5MmFWcE5qNWtfMk84ND…
Auna S.A. (AUNA) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPdFdTUExoYnYtZ21DZkR3QWhGSzJreV9jTHFpdTBIUWdjaTJTQnNneTFMZWExOXViSlZvRjZ2Tl9yaUNaX1BUOXptYlAySFhoaGFKa1lJck54R2w4cUo3a0d1WkE3ZXBtVjBaUFFxM0VyMlZGSUNuWmtncTBKSVdVYVFDRmJ5ejR2bGJzM1…
Auna (AUNA) Stock Rallies Lose Steam As Margin Strain Deepens - simplywall.st
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPc3VuY045bnh3d1k0Qy1FQlhkQnoySjhGZGRscFl0VVhLcmx5eXN2ZThaZi1ZUVlEblZTZmF0WkgzR3R3TWR3a0Q0S1ptS0VDRl9GZklYUF83Zk41YW52RGpfZTVpOXFOaGFZV2Y3WWgybm1PdmFhVTUxTFR4cUtHTWRVSFJhSjJ4bk1IUE…
AUNA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9HaEEwakRZdktEV0thUmV4NXJGLWNvTFlwTmxSdFY1OXZOQ2NWeUFoeVZETlNhYTh2clFWMjlscmxIUlV0Qm90dUNxTGNoVDlzLUYtSGpWV2puTDV5dXBtZHk4amZYU0xSX01ZV1draFBHVFBJU2Jv?oc=5" target="_blank">AUNA Fo…
Auna (AUNA) grows Q2 sales while earnings slide - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNR1VRSUFuUXEyaFhEN3pDWUZIcENCUGdUV1g4QmtDTUw0djBNZjJfSTlaREhTdUdwWlh4Um9pajJPbFE3STM0U1pDVzhYWEVVTTYwaGZkUHQtRkVrY29CQV9EUEVXTjZuNEFFamhoZlp1OVF3ZlMxbDBnVnJRWURUeVlTRnplYUFPY21MQm…
AUNA — Frequently Asked Questions
What is the current share price of Auna SA (AUNA)?
As of 2026-09-19 21:16 PDT, Auna SA (AUNA) trades at $5.24 on NYSE. Its 52-week range is $4.15 to $6.77.
What is the market capitalisation of AUNA?
Auna SA (AUNA) has a market capitalisation of $157.93M on NYSE.
What is the P/E ratio of AUNA?
AUNA trades at a trailing price-to-earnings (P/E) ratio of 87.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.71.
What is the return on equity (ROE) of AUNA?
AUNA has a return on equity (ROE) of 1.62%. Its return on capital employed (ROCE) is 11.21%.
Is AUNA a good stock to buy?
This page provides a data-driven analysis of Auna SA (AUNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.